- |
BCBSWY Humira Update
Effective July 1, 2025, Hadlima, Simlandi, adalimumab-aaty, adalimumab-adaz will be the preferred biosimilar products on all BCBSWY formularies while Humira is being removed from…
We comply with applicable Federal civil rights laws and do not discriminate on the basis of race, color, national origin, age, disability, or sex, including sexual orientation, gender identity, or gender expression. We also provide language assistance. Read our Nondiscrimination and Language Assistance notice.